

Special Issue

The Advance of Biomarker-Driven Targeted Therapies in Cancer

Message from the Guest Editors

The rise of biomarker-driven targeted therapies marks a pivotal moment in cancer treatment, ushering in personalized approaches that leverage the distinct molecular traits of tumors. This Special Issue delves into the forefront of biomarker identification, validation, and application within the realm of targeted cancer therapies. Ranging from genomic alterations to protein expression patterns, the unraveling of biomarkers empowers clinicians to stratify patients, anticipate treatment responses, and refine therapeutic strategies more precisely. Additionally, this edition aims to spotlight the dynamic landscape of precision medicine, showcasing innovative technologies and computational tools instrumental in biomarker discovery and clinical translation. By presenting cutting-edge research and clinical perspectives, this Special Issue aims at deepening our comprehension of biomarker-guided targeted therapies and their profound impact on both the tumor microenvironment and immune therapy, ultimately advancing patient outcomes in cancer care.

Guest Editors

Dr. Tianshun Zhang

Dr. Qiushi Wang

Dr. Ann Bode

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/199049

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)